

**IN THE HIGH COURT OF AUSTRALIA  
SYDNEY REGISTRY**

**BETWEEN:**



No S 54 of 2015

**ASTRAZENECA AB  
FIRST APPELLANT**

**ASTRAZENECA PTY LIMITED  
ACN 009 682 311  
SECOND APPELLANT**

**APOTEX PTY LTD  
ACN 096 916 148  
RESPONDENT**

**BETWEEN:**

No S 55 of 2015

**ASTRAZENECA AB  
FIRST APPELLANT**

**ASTRAZENECA PTY LIMITED  
ACN 009 682 311  
SECOND APPELLANT**

**ACTAVIS PHARMA PTY LTD  
(FORMERLY WATSON PHARMA PTY LTD)  
ACN 147 695 225  
RESPONDENT**

**BETWEEN:**

No S 56 of 2016

**ASTRAZENECA AB  
FIRST APPELLANT**

**ASTRAZENECA PTY LIMITED  
ACN 009 682 311  
SECOND APPELLANT**

**ASCENT PHARMA PTY LTD  
ACN 118 734 795  
RESPONDENT**

**APPELLANTS' CHRONOLOGY**

---

**Date of document:** 8 April 2015

Filed on behalf of the appellants by:

**ASHURST AUSTRALIA**  
Level 26, 181 William Street  
MELBOURNE VIC 3000

Tel (03) 9679 3000  
Fax (03) 9679 3111  
Ref: MLP GF 03 2018 9753  
Contact: Grant Fisher

10

20

30

**Part I: Suitable for publication**

This chronology is in a form suitable for publication on the Internet.

**Part II: Chronology**

Date	Event	Appeal Book reference
June 1991 to June 1996	Shionogi conducts preliminary studies, Phase I and early Phase II clinical trials in relation to rosuvastatin.	
7 January 1993	EP 0521471 (the 471 Patent) prior art is published.	
February 1997	Watanabe prior art is published (Watanabe et al, "Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptanoates, a novel series of HMG CoA reductase inhibitors" <i>Bioorganic &amp; Medicinal Chemistry</i> 1997 (5) 2).	
23 December 1997	Inventorship Record for Dr Ali Raza in relation to the 051 Patent.	
18 May 1998 to 19 January 1999	AstraZeneca conducts Phase I and Phase II/III clinical trials in relation to rosuvastatin.	
6 February 1999	Priority date of 051 Patent.	
1 February 2000	Complete specification for the 051 Patent filed (as PCT/GB00/00285).	
10 August 2000	Complete specification for the 051 Patent published internationally as WO 00/45819.	
25 August 2000	051 Patent open for public inspection.	
20 May 2004	051 Patent sealed.	
18 May 2011	Apotex commences proceedings in the Federal Court against AstraZeneca seeking revocation of the 051 Patent.	
6 December 2011	AstraZeneca cross-claims against Apotex for infringement of the 051 Patent.	
23 December 2011	Watson commences proceedings in the Federal Court against AstraZeneca seeking revocation of the 051 Patent.	

Date	Event	Appeal Book reference
20 January 2012	AstraZeneca cross-claims against Watson for infringement of the 051 Patent.	
10 February 2012	AstraZeneca commences proceedings in the Federal Court against Ascent for infringement of the 051 Patent.	
13 March 2012	Ascent cross-claims against AstraZeneca seeking revocation of the 051 Patent.	
22 October 2012 to 9 November 2012	Hearing (first instance trial) before Justice Jagot in Federal Court.	
5 March 2013	Justice Jagot delivers judgment.	
9 April 2013	AstraZeneca files Notices of Appeal in the Full Court of the Federal Court of Australia.	
15 April 2013	Sections 22A and 138(4) of the <i>Patents Act 1990</i> (Cth) come into effect by force of amendments made by the <i>Intellectual Property Laws Amendment (Raising the Bar) Act 2012</i> (Cth).	
11 June 2013	Shionogi assigns any and all right, title and interest that Shionogi may have had in and to the invention described and claimed in the 051 Patent to AstraZeneca.	
13 June 2013	AstraZeneca files interlocutory application seeking to amend its Notices of Appeal to rely on the Shionogi assignment and section 22A of the <i>Patents Act 1990</i> (Cth).	
31 July 2013 to 2 August 2013	Hearing before Full Federal Court.	
12 August 2014	Full Federal Court dismisses AstraZeneca's appeal and interlocutory application dated 13 June 2013.	
13 March 2015	High Court of Australia (French CJ and Hayne J) grant special leave to appeal.	

**DATED:** 8 April 2015

**A J L Bannon, C Dimitriadis, C Burgess** – Counsel for the appellants  
Tel: (02) 9930 7900; Fax: (02) 9223 2177

